Trial Profile
Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 as Monotherapy and in Combination With AMG 404 in Subjects With Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Etevritamab (Primary) ; Zeluvalimab (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 01 Oct 2021 Status changed from active, no longer recruiting to completed.
- 06 Aug 2021 Planned End Date changed from 31 Dec 2021 to 8 Oct 2021.
- 10 Dec 2020 Planned End Date changed from 16 Jun 2021 to 31 Dec 2021.